WOMENS ISCHEMIC SYNDROME EVALUATION

UAB是参与由NHLBI赞助的女性缺血综合征评估(WISE)的四个临床网站之一。WISE是一项为期3年的研究，旨在开发更好的工具来检测女性心肌缺血。基本的前提是，目前所有可用的临床测试在检测女性心肌缺血方面的可靠性低于男性。在UAB，我们计划评估静息/潘生丁心肌灌注检测缺血的敏感性和特异性，同时用Gd-MRI和混合Tl/Sestamibi闪烁成像进行评估。其他机构将测试不同的方法，包括核磁共振冠状动脉造影术、多巴酚丁胺核磁共振标记、多巴酚丁胺超声心动图、PET和心肌声学造影术。UAB的一个由234名妇女组成的研究小组，其中30%是少数民族，将与其他参与WISE中心收集某些共同数据，包括详细的心理社会/症状问卷、女性激素评估、动态心电和冠状动脉造影术。在诊断测试完成后，将在研究期间每隔6个月进行一次电话联系，以评估生命状况和发病率。

UAB is one of four clinical sites participating in the Women's Ischemic Syndrome Evaluation (WISE), sponsored by the NHLBI. WISE is a 3 year study which seeks to develop better tools for detecting myocardial ischemia in women. The underlying premise is that all currently available clinical tests have a lower reliability for detecting myocardial ischemia in women than in men. At UAB, we plan to evaluate the sensitivity and specificity of detecting ischemia with rest/persantine myocardial perfusion as assessed simultaneously by gadolinium-MRI and by hybrid thallium/sestamibi scintigraphy. Other institutions will be testing different modalities including MRI coronary arteriography, dobutamine MRI tagging, dobutamine echocardiography, PET, and myocardial contrast echocardiography. A study group of 234 women at UAB, 30% minority, will have certain common data collected with the other participating WISE centers, including a detailed psychosocial/symptoms questionnaire, female hormone assessment, ambulatory ECG and coronary arteriography. Following completion of diagnostic testing, telephone contact will be made at 6 month intervals for the duration of the study to assess vital status and morbidity.